StockWireNews

(ATNM) Could Be Cooking Again After More Breaking News Today (New 52-Week High Reached)

November 3rd

Greetings Readers,

ATNM needs full attention once again this week.

Another big press release was just dropped by the company. Check it out:

Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial

• 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches
• Patients on study received a median of 2 lines of prior therapy with 57% receiving prior treatment with venetoclax and 67% had adverse cytogenetics with 52% of patients having a TP53 mutation
• Data accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Symposium on Saturday, December 10th at 10:30 AM CT

NEW YORK, Nov. 3, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted positive results from the Phase 1 trial evaluating Actimab-A with salvage chemotherapy regimen CLAG-M in fit patients with relapsed or refractory acute myeloid leukemia (AML) that is being conducted at the Medical College of Wisconsin as investigator sponsored study. These data were detailed in an abstract accepted for oral presentation at the 64th Annual ASH Meeting & Symposium being held December 10-13, 2022 in New Orleans, Louisiana.

...

Read the full article here.

With this news, ATNM is off to a solid green start today and just reached a new 52-week high of $15.02. Make sure to keep a close eye on it.

Plus don't forget this announcement from earlier this week. H.C. Wainwright raised their already massive ATNM price target from $45 to $53.

Drop everything and get ATNM on radar now.

-----

*Actinium Pharmaceuticals, Inc. (ATNM)*

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs.

And ATNM has 4 potential catalysts to pay attention to right now. Check them out:

No. 1 - Bullish Triggered Technicals Galore

No. 2 - Low Float Volatility Possible On Daily Basis

No. 3 - Cantor Fitzgerald Initiates Coverage With $20 Target

No. 4 - Company Update Presents A Possibly Mind-Blowing Q4

But more on those in a second...

-----

There is Demand For a Leukemia Cure... and the Market Looks Lucrative

The leukemia therapeutics market could reach $17.1Bn by 2024 from $12.3Bn in 2019, at a CAGR of 6.8%.

Do you know what’s driving this market?

A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The increasing number of approvals of novel & innovative dr-ugs and immunotherapies is evidence of an increasing need for leukemia therapies.

Say hello to a wide-open opp. for Actinium Pharmaceuticals (ATNM).

Treatment options for AML, or acute myeloid leukemia, is precisely an unmet need- especially for those under 45. According to Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, as quoted by Check Rare, it is rarely diagnosed in patients under the age of 45. (1)

At the moment, the five-year survival rate for those 20 and older is also putrid 26%. (2)

Some must also contend with relapsed, or recurrent, acute myelogenous leukemia (AML), which means leukemia came back after treatment and after reaching remission. Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells. (3)

Actinium’s Iomab-B Could Be Nearing a Treatment With SIERRA trials

On September 15, 2021, Actinium announced enrollment for its pivotal Phase III SIERRA trial of Iomab-B was complete.

SIERRA is a 153-patient, multicenter, randomized trial studying Iomab-B, an antibody-radiation conjugate comprising an anti-CD45 antibody and radioactive iodine-131 (I-131), compared with salvage chemotherapy inactive, relapsed, or refractory acute myeloid leukemia (AML).

“Iomab-B was developed to address the significant unmet need of patients who could benefit and possibly be cured of their blood cancer with a bone marrow transplant but could not receive a transplant because non-targeted conditioning regimens could not produce a remission or are too toxic in this patient population. We are confident that Iomab-B will squarely address this unmet need given its targeted nature and ability to deliver high amounts of radiation directly to the bone marrow resulting in myeloablation while sparing healthy organs,” said Dr. Avinash Desai, Actinium Pharmaceuticals’ Executive VP, Clinical Development. (4)

The company’s Chief Medical Officer, Avinash Desai said:

“The remarkably consistent and high rates of BMT engraftment together with the low rates of non-relapse transplant-related mortality at day 100 with Iomab-B through 100% enrollment give us great confidence in SIERRA.”

In short, if things continue progressing the way they are and Q4 topline data is impressive, Actinium Pharmaceuticals (ATNM) could become a game-changer.

Read the company presentation here.

-----

And as I mentioned above ATNM has 5 potential catalysts to know right now. Here they are:

No. 1 ATNM Potential Catalyst - Bullish Triggered Technicals Galore

I'm telling you right now... Don't discount ATNM's technical indicators.

At close on Friday, ATNM was displaying several triggered technical indicators across the short, medium term, and long term.

Barchart was reporting these technical indicators as triggered:

Short Term Indicators

• 20 Day Moving Average
• 20 - 50 Day MACD Oscillator
• 20 - 100 Day MACD Oscillator
• 20 - 200 Day MACD Oscillator

Medium Term Indicators

• 50 Day Moving Average
• 50 - 100 Day MACD Oscillator
• 50 - 150 Day MACD Oscillator
• 50 - 200 Day MACD Oscillator

Long Term Indicators

• 100 Day Moving Average
• 150 Day Moving Average
• 200 Day Moving Average
• 100 - 200 Day MACD Oscillator

The website also shares its all-important "TrendSpotter" composite indicator is triggered too.

Could this be a signal that ATNM is only starting to heat up after a recent green move last week?

-----

No. 2 ATNM Potential Catalyst - Low Float Volatility Possible On Daily Basis

According to the Yahoo Finance website, ATNM has a low float.

The website reports this profile to have approximately 24.29Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2022 positive company news (like Q4 topline data) help provide a near term spark?

-----

No. 3 ATNM Potential Catalyst - Cantor Fitzgerald Initiates Coverage With $20 Target

Last month, fi-nan-cial services company, Cantor Fitzgerald, tagged ATNM with a $20 target.

That provides this NYSE American profile with over 100% potential upside from its closing valuation Friday.

Here's some highlights from the Yahoo Finance article:

• The analyst believes that the SIERRA trial is the only randomized Phase 3 study that offers BMT as a treatment option for patients with active r/r Acute Myeloid Leukemia (AML).
• "We think it is essential to focus on a 'Goldilocks' approach in finding a dose/regimen that balances safety and efficacy," the analyst writes.
• The potential expansion of Iomab-B may also go beyond CD45 space, considering conditioning remains an integral part of adoptive cell therapies.
• "Actinium has already achieved proof of concept in some of these settings. We think this could dramatically expand the market opportunity and open the door for further partnerships, " Cantor writes.

-----

No. 4 ATNM Potential Catalyst - Company Update Presents A Possibly Mind-Blowing Q4

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones

• On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022
• Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022
• Additional updates on collaborations and pipeline progress demonstrating Actinium's leadership in the development of Actinium-225-based radiotherapies expected by year-end
• Approximately $116Mn in cash and cash equivalents at the end of Q2 2022 expected to fund key value creating clinical, regulatory and R&D milestones through mid-2025

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today provided a business update and outlook, highlighting upcoming clinical milestones. Key milestones expected before year-end include: topline results for the pivotal Phase 3 SIERRA trial for Iomab-B; survival data from the Actimab-A CLAG-M trial; and additional updates related to progress with the Company's collaborations and internal research programs.

...

Read the full article here.

-----

ATNM Recap - 4 Potential Catalysts Could Provide A Breakout Spark

No. 1 - Bullish Triggered Technicals Galore

No. 2 - Low Float Volatility Possible On Daily Basis

No. 3 - Cantor Fitzgerald Initiates Coverage With $20 Target

No. 4 - Company Update Presents A Possibly Mind-Blowing Q4

-----

Coverage is officially initiated on ATNM. When time permits, do this:

Get ATNM on your radar now.

Sincerely,

Kai Parker

StockWireNews

Source 1
Source 2
Source 3
Source 4

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)